期刊文献+

坎地沙坦联合胺碘酮预防心房颤动复发效果分析

下载PDF
导出
摘要 目的通过观察坎地沙坦联合胺碘酮预防心房颤动(简称房颤)复发的疗效,探讨坎地沙坦在房颤预防中的作用。方法将持续性房颤转复后患者60例按随机数字表法分为坎地沙坦与胺碘酮联合治疗组(治疗组)与胺碘酮治疗组(对照组),进行预防复发治疗,共观察9个月,观察复发率、复发时限、左房内径,并进行对比分析。结果治疗组与对照组相比,其房颤复发率显著降低(36.7%vs 63.3%,P<0.05),复发时限显著延长[(175.3±41.5)dvs(90.9±36.5)d,P<0.05]。治疗组左房内径于6个月及9个月后明显缩小,与治疗前及对照组比较差异均有统计学意义(P<0.05)。结论血管紧张素受体拮抗剂坎地沙坦在维持房颤患者窦性节律方面有明显作用。
出处 《实用临床医学(江西)》 CAS 2011年第2期36-37,共2页 Practical Clinical Medicine
  • 相关文献

参考文献5

  • 1Kumagai K,Nakashima H,Urata H,et al.Effects of an giotensin typel receptor antagonist on electrical and structuralremodeling in atrial fibrillation[J].J Am Coll Cardio1,2003,41(12):2197-2204.
  • 2Klein H U,Goette A.Blockade of atrial angiotensin Ⅱ typel receptors:a novel antia rrhythmic strategy to prevent atrialfibrillation?[J].J Am Coil Cardiol,2003,41(12):2205-2206.
  • 3Heusch G,Schulz R.Pathophysiology of the rennin-angiotensin-system in atrial fibrillation[J].Dtsch Med Wochenschr,2006,131(15):817-820.
  • 4王宏宇,胡大一.心房颤动与心力衰竭[J].中国医刊,2003,38(11):61-63. 被引量:6
  • 5徐成斌.心房颤动复发的非抗心律失常药物治疗探索[J].中华心血管病杂志,2009,37(7):666-669. 被引量:11

二级参考文献9

  • 1Nattel S,Burstein B,Dobrev D.Atrial remoldeling and atrial fibrillation mechanism and implications.Circ Arrhythm Electrophysiol,2008,1:62-73.
  • 2Burstein B,Nattel S.Atrial fibrosis:mechanisms and clinical relevance in atrial fibrillation.J Am Coil Cardiol,2008,51:802-809.
  • 3Allessie M,Ausma J,Schotten U.Electrical,contractile and structural remodeling during atrial fibrillation.Cardiovasc Res,2002,54:230-246.
  • 4Wijffels MC,Kirehhof CJ,Dorland R,et al.Atrial fibrillation begets atrial fibrillation.A study in awake chronically instrumented goats.Circulation,1995,92:1954-1968.
  • 5De Simone A,De Pasquale M,De Matteis C,et al.Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).Eur Heart J,2003,24:1425-1429.
  • 6Fetsch T,Bauer P,Engberding R,et al.Prevention of atrial fibrillation after cardioversion:results of the PAFAC trial.Eur Heart J,2004,25:1385-1394.
  • 7Nishida K,Fujiki A,Sakamoto T,et al.Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial tschycatdia.J Cardiovasc Eleetrophysiol,2007,18:765 -772.
  • 8Laily JA,Gnall EM,Seltzer J,et al.Non-antiarrhythmic drugs in atrial fibrillation:a review of non-antiarrhythmie agents in prevention of atrial fibrillation.J Cardiovasc Electrophysiol,2007,18:1222-1228.
  • 9GISSI-AF Investigators,Disertori M,Latini R,et al.Valsartan for prevention of recurrent atrial fibrillation.N Engl J Med,2009,360:1606-1617.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部